Receive Alzheimer's treatment and prevention news and analysis from our experts.

0

New Research for Alzheimer’s Treatment

Posted by on Monday, May 23rd, 2016

research for Alzheimer's treatment

 

Despite many encouraging leads, new  Alzheimer’s Treatment is “slow to emerge,”according to Mayo Clinic.  The good news is that as time progresses, a better understanding of how Alzheimer’s affects the brain has given scientists more of a clear understanding of new ways to implement effective treatment of the disease.  Continue reading to learn more about  Mayo Clinic’s report regarding some of these promising new research studies.

Continue reading…

0

Research Community Discusses Interventions for Alzheimer’s Treatment and Prevention

Posted by on Sunday, November 23rd, 2014


The International Conference on Clinical Trials for Alzheimer’s Disease in Philadelphia, (also referred to as the CTAD) recently met to gather information regarding current research initiatives showing the most promise for Alzheimer’s treatment and prevention.

 

CATD for Alzheimer's treatment

 

The CTAD began in 2008 and since that time has continued its function to provide a platform for professional research experts from around the globe to come together in collaboration regarding research that may lead to new intervention and prevention modalities for AD.  The disease effects 5.4 million people in American and nearly 36 million (with AD and related dementias) world-wide-and by the year 2050 that number is expected to grow to an astounding 115 million.  In fact, if successful intervention is not achieved in the next 35 years, many experts project that Alzheimer’s disease may cost more than any other major illness in the healthcare industry-worldwide.

Top researchers around the globe came together for this year’s conference to discuss Alzheimer’s treatment and AD prevention and treatment clinical research trials that exhibit the most hope for the future.  Other topics of discussion included-a strategy for new treatment alternatives for mild to moderate Alzheimer’s disease, as well as new drug treatment for some of the most disconcerting symptoms of the disease.

The conference was chaired by  Paul Aisen, MD, University of California at San Diego; Bruno Vellas, MD, University of Toulouse; Jacques Touchon, MD, University of Montpellier;  and Michael Weiner, MD, University of California at San Francisco.

According to the director of the Alzheimer’s Disease Cooperative Study (and Co-Organizer of the CTAD Conference), Paul Aisen, MD:  “As evidenced by the research being presented this year, efforts to develop effective treatments for Alzheimer’s disease have been focused on the earliest stages of the disease, before symptoms are even apparent—but the needs of people already diagnosed have not been forgotten.”

The following topics discussed at the conference will be covered in subsequent blog entries:

Preventing Alzheimer’s By Treating Early

New Alzheimer’s  Treatment Strategies for Mild to Moderate AD

Treating the most troubling symptoms in AD